Paediatric antiretroviral therapy.
|
|
- Bonnie Jacobs
- 5 years ago
- Views:
Transcription
1 Paediatric antiretroviral therapy. Guidelines exist for the choice of first line agents, but do not cover second line agents, other than recommending regimes of adequate potency. We would follow PENTA guidelines, when initiating therapy and then further treatment options would be directed by side effect profile and resistance findings. All the doses in the attached formulary match the PENTA guidelines, and these formulations should be available to the paediatric population at LTH. This has been updated to represent the changes recommended in PENTA 2015.
2 Paediatric HIV formulary NRTI Dosage Formulation Important Side Effects Abacavir (ABC) Liquid: > 3 months: 8mg/kg bd or 16mg/kg od (max. 600mg daily) > 12 years: 300mg bd or 600mg od Tablets: 14-21kg: 300mg od or 150mg bd 21-30kg: 450mg od or 150mg om + 300mg on >30kg/Adult: 600mg od or 300mg bd Tablet: 300mg (yellow, scored) Liquid: 20mg/ml (240ml sugar-free, banana and strawberry flavour, 2 month expiry) Hypersensitivity reaction: fever, rash, nausea, vomiting, dyspnoea, cough, diarrhoea, lethargy GI disturbances Lactic acidosis Advice 1. How to recognise signs of hypersensitivity 2. Importance of regular dosing 3. Can be given with or without 4. Can be crushed and mixed with a small amount of water or Other Total daily dose may be given in 2 divided doses Hypersensitivity reactions may occur within first 6/52 Do HLA-B*5701 test before starting Contraindicated in severe hepatic Didanosine (ddl) Liquid: 3 months - 8 months 100mg/m 2 bd 8 months - 18 years: mg/m 2 od, usual dose 200mg /m 2 od; maximum 400mg od Child dosing using capsules > 6 years and 20-25kg: 200mg od 25-60kg: 250mg od Adult (<60kg): 250mg od (200mg od if coprescribed with tenofovir) (>60kg): 400mg od (250mg od if coprescribed with tenofovir) Tablets (with calcium and magnesium antacids): 25mg Capsules EC: 125mg, 200mg, 250mg, 400mg Powder for oral solution: 10mg/ml (refrigerate, stable for 30days) Peripheral neuropathy, pancreatitis, nausea, diarrhoea Lipodystrophy, lactic acidosis and pancreatitis enhanced in combination with stavudine Antacid tablets: 1. Each dose should be taken as at least 2 tablets (child <1year, 1 tablet) to ensure sufficient antacid 2. Chew thoroughly, crush or disperse in water/clear apple juice 3. Take 2 hours after lopinavir+ritonavir or atazanavir+ritonavir EC capsules: 1. Swallow capsules whole either 2 hours before or 2 hours after 2. Caps can be opened and sprinkled on e.g. yogurt results in decreased exposure. Oral solution: Reconstitute with water and Mylanta Extra strength or Maalox Plus antacid suspensions Discontinue treatment if pancreatitis symptoms develop Not recommended with TDF Should be given on an empty stomach (2hours after and 1 hour before or milk) Reduce dose in renal
3 Emtricitabine (FTC) Child dosing liquid >4 months: 6mg/kg od (max. 240mg od) (FDA approval from 0 months of age) >33kg: 240mg od Child dosing capsules >33kg: 200mg od Capsule: 200mg (white/blue) Liquid: 10mg/ml (170ml, orange, candyflavoured) Contains propylene glycol and kept in the fridge. Headache, diarrhoea, nausea, rash Skin pigmentations on palms and soles, abnormal dreams Exacerbation of hepatitis B on discontinuation 1. Can be administered with or without 240mg oral solution 200mg capsule Dose reduce in renal Do not give with 3TC Lamivudine (3TC) Child dosing liquid Neonate (<30days): 2mg/kg bd 1-3months: 4mg/kg bd 3months - 12years: 4mg/kg bd or 8mg/kg od (max. 300mg/day) Child dosing tablet 14-21kg: 75mg bd or 150mg od 21-30kg: 75mg om + 150mg on or 225mg od >30kg: 150mg bd or 300mg od Tablet: 100mg (butterscotch colour), 150mg (scored, white, Epivir) 300mg (grey, Epivir) Liquid: 50mg/5ml (240ml, banana and strawberry flavour, Epivir, 30 day expiry) Nausea, diarrhoea, headache, fatigue Exacerbation of hepatitis B on discontinuation 1. Can be given with or without 2. Can be crushed and mixed with a small amount of water or Reduce dose in renal Adult >12 years: 150mg bd or 300mg od Tenofovir (TDF) Child dosing granules (1 scoop (scp) = 40mg) 2-8 years: 8mg/kg od 10-12kg 2scp OD 12-14kg 2.5scp OD 14-17kg 3scp OD 17-19kg 3.5scp OD 19-22kg 4scp OD 22-24kg 4.5scp OD 24-27kg 5scp OD 27-29kg 5.5scp OD Granules TDF 40mg/1g scoop (33mg/g TD) Tablets TDF 150/200/250mg (white) TDF 300mg (blue) Headache, nausea, vomiting Renal tubular dysfunction, bone demineralisation Exacerbation of hepatitis on discontinuation 1. Take with or after 2. Tablet can be dispersed in half a glass of water, orange juice or grape juice (bitter taste) Dose reduce in renal Measure baseline renal function, then 4 weekly for 1 year, then 3 monthly Not recommended with ddl
4 29-32kg 6 scp OD 32-34kg 6.5scp OD 34-35kg 7scp OD >35kg 7.5scp OD Child dosing tablets >2 years 17-22kg 150mg OD 22-28kg 200mg OD 28-35kg 250mg OD >35kg 300mg OD Adults 300mg OD (<18yrs: Doses based on tenofovir disoproxil fumarate 300mg 245mg tenofovir disoproxil (as fumerate))
5 Zidovudine (AZT) Stavudine (d4t) NOT USED AS STANDARD Child dosing liquid: >4kg (birth) to <9kg: 12mg/kg bd (max. 300mg bd) >9kg to 30kg: 9mg/kg bd (max. 300mg bd) >30kg: 300mg bd Child dosing capsules 8-13kg: 100mg bd 14-21kg: 100mg om + 200mg on 22-30kg: 200mg bd >30kg 300mg BD Neonate (<13 days): 0.5mg/kg bd <30kg: 1mg/kg bd 30-60kg: 30mg bd >60kg: 40mg bd Capsules: 100mg (white/blue band), Liquid: 50mg/5ml (200ml, sugar-free, strawberry flavoured, 30 day expiry) IV infusion also available Capsules: 20mg (brown), 30mg (light orange/dark orange), 40mg (dark orange) Liquid: 1mg/ml (200ml, powder for reconstitution, cherry flavoured) Granulocytopenia and/or anaemia Nausea, headache, myopathy, hepatitis, nail pigmentation, neuropathy Peripheral neuropathy, pancreatitis, hepatitis, GI disturbances, headache, rash Lipodystrophy, lactic acidosis and pancreatitis enhanced in combination with didanosine 1. Can be given with or without 2. Capsules can be opened and dissolved in water 1. At least one hour before Monitor full blood count after 4/52 treatment, then every 3 months Don t give with stavudine Reduce dose in severe renal Reduce dose in hepatic Switch to alternative antiretroviral if peripheral neuropathy develops Don t give with Zidovudine Reduce dose in renal
6 NNRTI Dosage Formulation Important Side Effects Efavirenz (EFV) Child (3-5years liquid only): 13-15kg: 360mg on 15-20kg: 390mg on 20-25kg: 450mg on kg: 510mg on Child dosing capsules for > 5 year (liquid in brackets): 13-15kg: 200mg on (liq: 270mg on) 15-20kg: 250mg on (liq: 300mg on) 20-25kg: 300mg on (liq: 360mg on) kg: 350mg on (liq: 450mg on) kg: 400mg on (liq: 510mg on) Adult tablets >40kg: 600mg on (liq: 720mg on) Capsules: 50mg (yellow/white), 100mg (white), 200mg (yellow) Tablets: 600mg (yellow) Liquid: 30mg/ml (180ml, sugar-free, strawberry and mint flavoured) Liquid is not bioequivalent to tabs or caps. No PK data on liquid for child < 13kg - use capsules as sprinkles) Rash, mood changes, vivid dreams, hyperchloresterolemia, abdominal pain Advice 1. Tablets can be cut 2. Capsules can be opened and added to liquids or a small amount (1-2 teaspoons) of (has a peppery taste) 3. Give tablets/capsules an hour before or on an empty stomach 4. Preferably give dose at bedtime to reduce CNS side effects 5. High fat meal can increase the EFV exposure. Other No dose adjustment necessary in renal Contraindicated in severe hepatic
7 Etravirine (ETR) Child: >6 years 16-20kg 100mg BD 20-25kg 125mg BD 25-30kg 150mg BD >30kg 200mg BD Adult: 200mg BD Tablets: 25mg, 100mg, 200mg ( all white) Rash (more common in females, usually resolves within 2 weeks), hypersensitivity reactions (most commonly during week 3-6 of treatment) Diarrhoea, flatulence, abdominal pain, headache, pruritis 1. How to recognise signs of hypersensitivity reactions 2. Take with or after 3. Can disperse tablets in water just prior to administration AUC decreased by 50% if taken on an empty stomach Not recommended in severe hepatic Nevirapine (NVP) PRESCRIBE GENERICALLY Child (from birth)immediate release formulations: 4mg/kg OD for 14 days (max 200mg/day), then (<8 years) 7mg/kg BD or (> 8 years) 4mg/kg BD (max 400mg/day) if no rash or LFT abnormalities. Child (> 3 years) extended release formulations: 13kg - 22kg 200mg OD 23kg - 35kg 300mg OD >35kg 400mg OD Immediate release tablets: 200mg (white, scored), Modified release tablets 50mg, 100mg and 400mg (all yellow) Liquid: 50mg/5ml (240ml, six months expiry) Rash, hepatitis, Steven- Johnson syndrome - usually within the first 12 weeks Nausea, headache 1. How to recognise signs of hypersensitivity reactions or hepatitis symptoms 2. Can be administered with or without 3. The MR tablets must be swallowed whole Baseline LFTs, then every 2 weeks for 2 months, then after a month, then regularly No dose adjustment necessary in renal All patients must be initiated on 14 days immediate release Adult: 200mg od 14 days, then increase to 200mg bd or 400mg M/R od if no rash or LFT abnormalities
8 Rilpivirine (RPV) Child: Not recommended Adults ( >18 years) 25mg OD Tablets: 25mg (White) Should be taken with. Exposure is 40% lower on an empty stomach. Caution in severe renal Not recommended in severe hepatic
9 Atazanavir (ATV) Darunavir (DRV) PI Dosage Formulation Important Side Effects Child(6-18years): 15-20kg: 150mg od (+RTV 100mg od) 20-40kg: 200mg od (+RTV 100mg od) >40kg: 300mg od (+RTV 100mg od) Adult: 300mg od (+RTV 100mg od) Child dosing liquid (> 3 years) 10-11kg 200mg BD + RTV 32mg BD 11-12kg 220mg BD + RTV 32mg BD 12-13kg 240mg BD + RTV 40mg BD 13-14kg 260mg BD + RTV 40mg BD 14-15kg 280mg BD + RTV 48mg BD 15-30kg 380mg BD + RTV 50mg BD 30-40kg: 460mg BD + RTV 60mg BD >40kg 600mg BD + RTV 100mg BD Capsules: 150mg (dark blue/light blue), 200mg (dark blue), 300mg (red/blue) Tablets: 75mg (white), 150mg (white), 400mg (light orange), 600mg (orange), 800mg (red) Liquid: 100mg/ml (white suspension) Nausea, headaches, rash, jaundice, elevated total bilirubin Mouth ulcers, dry mouth, hypertension, syncope Haematemesis, chest pain, myocardial infarction Rash, nausea, diarrhoea, headache Contains sulphonamide moiety - check allergies Especially co-trimoxazole Advice 1. Give with or after 2. Avoid indigestion remedies 3. Do not open capsules Other Contraindicated with PPIs Contraindicated in moderate or severe hepatic 1. Give with or after Contraindicated in severe hepatic Child dosing tablets (>3 years) 15-30kg: 375mg BD + RTV 50mg BD 30-40kg: 450mg BD + RTV 60mg BD >40kg: 600mg BD + RTV 100mg BD
10 Adult (ART experienced) 600mg BD + RTV 100mg BD OR 800mg OD + RTV100mg OD
11 Fosamprenavir (FPV) Liquid (>6 years): 25-32kg: 18mg/kg bd (+ RTV 3mg/kg bd) 33-38kg: 18mg/kg bd (+ RTV 100mg bd) >39kg: 700mg bd (+ RTV 100mg bd) Tablets >39kg:700mg bd or 1400mg od (+ RTV 100mg bd) Tablets: 700mg (pink) Liquid: 50mg/ml (grapebubblegum and peppermint flavoured) Rash Perioral paraesthesia, nausea, diarrhoea 1. Give liquid with or after 2. Take tablets with or without Rash may occur within two weeks. Discontinue if severe or associated with systemic/allergic symptoms or mucosal involvement. If mild/moderate usually resolves within 2 weeks Complex interactions Reduce dose in hepatic Lopinavir (+ritonavir) (LPV/r) (Kaletra) Child dosing liquid (without EFV/NVP) 14 days - 6 months 300/75mg/m 2 BD 6 months - 18 years 230/57.5mg/m 2 BD (max 400/100mg BD) (with EFV/NVP) 6 months - 18 years 300/75mg/m 2 BD Tablets: 200mg LPV/ 50mg RTV (yellow), paed tablet: 100mg LPV/25mg RTV (pale yellow) Liquid: 400mg LPV/100mg RTV / 5ml (yellow, store in the fridge) Diarrhoea, headache, nausea, vomiting, electrolyte disturbances Cautious use in hepatic insufficiency 1. Liquid tastes bitter 2. Give liquid with or after 3. Tablets can be given with or without 4. Do not crush tablets Contraindicated in severe hepatic Child dosing tablet (without EFV/NVP) 15-25kg 200/50mg BD 25-35kg 300/75mg BD >35kg 400/100mg BD (with EFV/NVP) 15-20kg 200/50mg BD 20-30kg 300/75mg BD 30-45kg 400/100mg BD >45kg 500/125mg BD Adult 400/100mg BD
12 Ritonavir (RTV) For boosting other PIs. See specific Tablets: 100mg (white) Liquid: 80mg/ml (sugarfree) Contains 42% alcohol and 266mg/ml propylene glycol which can be toxic esp in premature neonates Perioral paraesthesia, nausea, diarrhoea, flushing, rash 1. Give with or after 2. Oral solution can be mixed with chocolate milk to mask bitter taste 3. Do not mix oral solution with water, ensure measuring cup is dry before using If on RTV + ddl, separate administration by at least two hours Increasing reports of Cushing s symptoms in patients on RTV and steroids (mainly fluticasone/triamcinolone) (including intranasal/topical/intraarti cular)
13 Fusion and Entry Inhibitors Maraviroc (MVC) Enfuviritide (T-20) Dosage Formulation Important Side Effects Child: Seek specialist advice Adult (> 40kg): 150mg bd (with CYP3A4 inhibitor) 600mg bd (with potent CYP3A4 inducer) 300mg bd (with NVP) Child (6-16 years): 2mg/kg bd (max. 90mg bd) Adult: 90mg bd Tablets: 150mg, 300mg (blue, film-coated) Subcutaneous injection: 108mg powder for reconstitution (90mg/ml when reconstituted with 1.1ml water for injection) Nausea, vomiting, abdominal pain, constipation, headache, dizziness, pruritus Local injection site reactions Nausea, vomiting, abdominal pain, constipation, diarrhoea Advice 1. Can be given with or without Other Reduce dose in renal Only to be given for CCR5 topic virus When reconstituting, allow to stand for up to 45 minutes to dissolve, do not shake or invert the vial
14 Integrase Inhibitors Dolutegravir (DTG) Dosage Formulation Important Side Effects 15-20kg 20mg OD 20-30kg 25mg OD 30-40kg 35mg OD Tablets 10mg, 25mg 50mg (yellow) Advice Should be taken with to enhance exposure Other Elvitegravir (ELV) Raltegravir (RAL) Child >12 years and >40kg (without integrase resistance) 50mg OD (with integrase resistance) 50mg BD (with potent CYP3A inducers, EFV, FOS/r, rifampicin) 50mg BD >18 years (with ATV) 85mg OD + RTV 100mg OD (with LPV) 85mg OD + RTV 100mg BD (with DRV, FOS) 150mg BD + RTV 100mg BD Child dosing chewable tablet 11-14kg: 75mg BD 14-20mg 100mg BD 20-28kg 150mg BD 28-40kg 200mg BD >40kg 300mg BD Child dosing film coated tablet >6 years and >25kg 400mg BD Tablets 85mg (green), 150mg (green) Tablets: 400mg (pink) Chewable tablet: 25mg (pale yellow) and 100mg (pale orange) Suspension and chewable tablets are not bioequivalent to film coated tablets Nausea, dizziness, insomnia, rash, pancreatitis, elevated ALT, AST, Gamma GT Tablets must not be cut Should be taken with 1. Swallow whole, do not chew (except chewable tablets) 2. Can be given with or without 3. Avoid indigestion remedies 4. Chewable tablets contain phenylalanine CYP450 interactions unlikely Adult (>16 years): 400mg BD
15
16 Combination Preparations Atripla Combivir (AZT + 3TC) Dosage Formulation Important Side Effects Child: Individual TDF + FTC + EFV doses- max. dose for adults Adult (>12 years and > 40kg): 1 od Child 14-21kg: ½ tablet bd Child 21-30kg: ½ tablet om & 1 tablet on Adult (>30kg): 1 bd Efavirenz 600mg/emtricitabine 200mg/tenofovir 245mg tablets (pink) Zidovudine 300mg/lamivudine 150mg tablets Advice Give on an empty stomach (2 hours after ), preferably before bed time Can be administered with or without. Other Tablets should not be cut Tablets can be cut Can be crushed and added to a small amount of semi-solid or liquid Descovy Eviplera (FTC + RPV + TDF) Child >12 years (>35kg) Dose of Descovy Descovy 200/10 mg once daily Descovy 200/25 mg once daily Child: Not recommended >18 years: 1 tab OD Third agent in HIV treatment regimen Atazanavir with ritonavir or cobicistat Darunavir with ritonavir or cobicistat 1 Lopinavir with ritonavir Dolutegravir, efavirenz, maraviroc, nevirapine, rilpivirine, raltegravir Each tablet contains 200 mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 10 mg of tenofovir alafenamide. Emtricitabine 200mg/Rilpivirine 25mg/Tenofovir 300mg Can be administered with or without. Should be taken with Avoid when VL > 100,000 copies/ml Tablets should not be cut Tablets should not be cut Evotaz Child: Not recommended Unlicensed, but D&T agreed: >40kg/14 years and post pubescent 1 tab OD >18 years: 1 tab OD Each tablet contains atazanavir sulphate corresponding to 300 mg atazanavir and 150 mg of cobicistat. Should be taken with
17 Genvoya Child >12 years (>35kg) 1 tab OD Each tablet contains 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 10 mg of tenofovir alafenamide. Kivexa (ABC + 3TC) PRESCRIBE GENERICALLY Child (<40kg): Individual ABC + 3TC doses BD - max. dose for adults Child & Adult (>40kg): 1 od Abacavir 600mg/lamivudine 300mg tablets (orange) Should be taken with Can be administered with or without Tablets can be cut Odefesy Child >12 years (>35kg) 1 tab OD Each tablet contains 200 mg of emtricitabine, rilpivirine hydrochloride equivalent to 25 mg of rilpivirine and tenofovir alafenamide fumarate equivalent to 25 mg of tenofovir alafenamide. Rezolsta Stribild (ELV + COB + FTC+ TDF) Triumeq (DTG + ABC + 3TC) Trizivir (ABC + 3TC + AZT) Child: Not recommended Unlicensed, but D&T agreed: >40kg/14 years and post pubescent 1 tab OD >18 years: 1 tab OD Child: Not recommended >18 years: 1 tab OD Child (<40kg): Individual ABC + 3TC doses BD - max. dose for adults Child & Adult (>40kg): 1 od Child: Individual ABC + 3TC + AZT doses- max. dose for adults Adult (>18 years): 1 bd Each tablet contains 800 mg of darunavir (as ethanolate) and 150 mg of cobicistat elvitegravir 150mg + cobicistat 150mg + tenofovir 300mg + emtricitabine 200mg Lamivudine 50mg + Abacavir 300mg + Dolutegravir 600mg Abacavir 300mg/lamivudine 150mg/zidovudine Should be taken with Should be taken with Should be taken with Can be administered with or without Can be administered with or Tablets should not be cut
18 300mg tablets (blue-green) without Truvada (TDF + FTC) Child: Individual TDF + FTC doses- max. dose for adults >12years and >35kg: 1 od Tenofovir 245mg/emtricitabine 200mg tablets (blue) Should be taken with Tablets can be cut Can be crushed and added to liquid PCP Prophylaxis Co-trimoxazole <6 months: 120mg OD 6months-5 years: 240mg OD 6-14 years: 480mg OD >14 years: 960mg OD OR Child: 450mg/m 2 BD, three times per week. Dosage Formulation Important Side Effects Written by Jennifer Brown Specialist Clinical Pharmacist (Paediatric Medicine) Checked by Sian Collins, Advanced Clinical Pharmacist (Paediatric Medicine) November 2013 Liquid 240mg/5ml (white/yelloworange suspension) Tablets 480mg + 960mg Updated by Sian Shenton, Advanced Clinical Pharmacist (Paediatric Medicine) April 2017 Diarrhoea; headache; hyperkalaemia; nausea; rash Advice Can be administered with or without Other Discontinue immediately if blood disorders or rash (including Stevens- Johnson syndrome, toxic epidermal necrolysis, photosensitivity) develop. References: Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life BNF for children
Antiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)
More informationNorthwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care
Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care www.nwaetc.org The Northwest AIDS Education and Training Center (NW AETC), located at the University
More informationHIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir) Stavudine
More informationANTIRETROVIRAL TREATMENTS (Part 1of
CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after
More informationAntiretrovial Crushable/Liquid Formulation Chart
Antiretrovial Crushable/Liquid Formulation Chart Eliza Dollard, PharmD; Nafeesa Chin-Beckford, PharmD; Laura Aragon, PharmD Last Updated: 04/2016 Agent How Supplied Crushable Status **Products listed in
More informationThird Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily
Table I. Recommended and Alternative Antiretroviral Regimens (DHHS Guidelines, May 1, 2014) Recommended Regimens Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI) Third Agent Advantages Disadvantages
More informationABRIDGED ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
NULOESIDE/TIDE REVERSE TRANSRIPTASE INHIBITORS (N(t)RTIs) Abacavir AB (Ziagen) Emtricitabine FT (Emtriva) Lamivudine 3T (Epivir) Tenofovir disoproxil fumarate TDF (Viread) Zidovudine AZT, ZDV (Retrovir)
More informationMedscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection
Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Generic Name (Abbreviation) / Trade Name Abacavir (ABC) / Ziagen Trizivir with ZDV + 3TC Epzicom with 3TC Didanosine (ddi)
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationHIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More informationARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting
ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting Dr. Andrew D Kambugu, FRCP (UK) Infectious Diseases Institute, Makerere University Outline of Discussion Key Definitions
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationMedication Errors Focus on the HIV-Infected Patient
Medication Errors Focus on the HIV-Infected Patient Nimish Patel, Pharm.D., Ph.D., AAHIVP Associate Professor Albany College of Pharmacy & Health Sciences I do not have any conflict of interest in relation
More informationHuman Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications
Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications Carrie Allen PharmD, CGP, BCPS, BCPP, CCHP Overview - Part 2: HIV
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationHIV medications HIV medication and schedule plan
Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with
More informationThe ART of Managing Drug-Drug Interactions in Patients with HIV
The ART of Managing Drug-Drug Interactions in Patients with HIV Bradley L. Smith, Pharm.D. smith.bradley1@mayo.edu Pharmacy Grand Rounds December 19, 2017 2017 MFMER slide-1 Presentation Objectives Describe
More informationWOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /
More informationtreatment passport 1
treatment passport 1 Why keep a treatment history? Keeping a short record of your treatment history can help in many ways. It can help you understand your health and treatment. It can help if your doctor
More information2/10/2015. Switching from old regimens. HIV treatment revision: As simple as old versus new? What is an old regimen? What is an old regimen?
Switching from old regimens David Nolan Department of Immunology, Royal Perth Hospital, Western Australia Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia What is
More informationExploring HIV in 2017: What a pharmacist needs to know
Exploring HIV in 2017: What a pharmacist needs to know Lifecycle of the HIV virus a. HIV spread through mucous membrane contact, damaged tissue contact, or blood contact with: blood, semen, rectal fluids,
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationPage 1 of 5 ENLGLISH / ESPAÑOL / PORTUGUÉS / FRANÇAIS Share 3 Drug Chart for HIV Treatment CURRENT EDITION ABOUT SENSE BACK ISSUES MSMGF HOME CONTACT US There are a number of antiretroviral (ARV) medications
More informationHIV Management Update 2015
9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationORAL ANTIRETROVIRAL ADMINISTRATION: INFORMATION ON CRUSHING AND LIQUID DRUG FORMULATIONS
ORAL ANTIRETROVIRAL ADMINISTRATION: INFORMATION ON CRUSHING AND LIQUID DRUG FORMULATIONS Combination Products: Atripla (efavirenz/ emtricitabine/ tenofovir) no Consider use of Truvada tabs and efavirenz
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationAntiretroviral Drug Dosing in Pediatric Patients October 2014
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Abacavir (ZIAGEN, ABC) Neonatal/Infant: Not approved for infants < 3 months. Pediatric ( 3 months): 8 mg/kg/dose (maximum 300 mg) po BID If clinically
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationToo small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants
Too small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants Mark Mirochnick, MD Boston University School of Medicine, Boston, MA, USA Full Term Full Term 34 wks
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationList of Optimal Paediatric Formulations. Marianne Gauval (CHAI) IAS-ILF Round table Geneva, Switzerland 26 November 2013
List of Optimal Paediatric Formulations Marianne Gauval (CHAI) IAS-ILF Round table Geneva, Switzerland 26 November 2013 1 History of development of treatment options for children Adult tablets Syrups and
More informationCCC Guidance for Pediatric HIV PEP Outside of the Perinatal Period
CCC Guidance for Pediatric HIV PEP Outside of the Perinatal Period There are currently no published guidelines for post-exposure prophylaxis from the CDC/PHS specific to the pediatric population. This
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Antiretroviral Medications: What you need to know Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Associate Professor, Department of Pharmacy Practice Jefferson College of Pharmacy, Thomas Jefferson University
More informationHIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop
HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop Parya Saberi, PharmD, MAS The Medical Management of HIV/AIDS December 2012 Objectives What are commonly used ARVs and where do they work in
More informationHIV for the Non-ID Pharmacist
Disclosures HIV for the Non-ID Pharmacist I have nothing to disclose at this time Carmen Faulkner-Fennell, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist--Infectious Diseases Greenville Hospital System
More informationFLAMINGO 96-WEEK PRESENTATION DATA
FLAMINGO 96-WEEK PRESENTATION DATA Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects UK/DLG/0083/14j(3) Date of preparation: February 2017 Prescribing information is available at the
More informationEfavirenz, stavudine and lamivudine
efavirenz, stavudine, lamivudine: 1 efavirenz, stavudine and lamivudine First line ART treatment for HIV infection Efavirenz, stavudine and lamivudine efavirenz, stavudine, lamivudine: 2 Slide 1 Information
More informationSculpting a Better Regimen: The ART of HIV Medications
Sculpting a Better Regimen: The ART of HIV Medications Kelly Peddy, PharmD, MPA Clinical Pharmacy Specialist - Ambulatory Care Memorial Hospital of South Bend November 30, 2017 For HealthTrust Members
More informationREVIEW No Assessment of safety a. Have all relevant studies on safety been included Yes X No (if no, please provide reference and information)
Expert peer review on application for addition of fixed dose combination formulations of antiretroviral medications in the EML (Adults) REVIEW No. 2 Abacavir + lamivudine (ABC+ 3TC) Tablet (dispersible):
More informationQuick Reference Guide to Antiretrovirals. Guide to Antiretroviral Agents
Author: Malte Schütz, MD June 1, 2002 Quick Reference Guide to Antiretrovirals Regular updates to this publication are posted on the Medscape Web site at http://hiv.medscape.com/updates/quickguide. Please
More informationTreatment update. Bronagh McBrien June 2016
Treatment update Bronagh McBrien June 2016 Speaker Name Bronagh McBrien Statement Received educational funding and support from Gilead, Merck, Boehringer Ingelheim, Janssen-Cilag Date : 27 June 2016 BHIVA
More informationAdult Guidelines. Sipho Dlamini. Division of Infectious Diseases & HIV Medicine University of Cape Town Groote Schuur Hospital
Adult Guidelines Sipho Dlamini Division of Infectious Diseases & HIV Medicine University of Cape Town Groote Schuur Hospital Cape Town CME 3 rd June 2017 Sports Science Institute, Newlands Outline of talk
More informationAntiretroviral Drugs
Antiretroviral Drugs Dr Paddy Mallon UCD HIV Molecular Research Group Associate Dean for Research and Innovation UCD School of Medicine and Medical Science paddy.mallon@ucd.ie UCD School of Medicine &
More informationWESTERN CAPE ART GUIDELINES PRESENTATION 2013
WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory
More informationJULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet
JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationTRIUMEQ * (DTG/ABC/3TC): BIOEQUIVALENCE DATA
TRIUMEQ * (DTG/ABC/3TC): BIOEQUIVALENCE DATA *In studies supporting TRIUMEQ, DTG 50 mg + ABC 600 mg/3tc 300 mg were used. Bioequivalence has been demonstrated. DTG, dolutegravir; ABC, abacavir; 3TC, lamivudine
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationPaediatric HIV Resistance. Mohern Archary Paediatric Infectious Diseases Unit King Edward VIII Hospital / University of KwaZulu Natal
Paediatric HIV Resistance Mohern Archary Paediatric Infectious Diseases Unit King Edward VIII Hospital / University of KwaZulu Natal Preliminary evaluation of referrals for Antiretroviral Therapy (ART)
More informationJames Nuttall Paediatric Infectious Diseases Unit Red Cross Children s Hospital
James Nuttall Paediatric Infectious Diseases Unit Red Cross Children s Hospital Paediatric HIV Infection Symposium, August 21, 2010, Red Cross Children s Hospital Overview of talk The 2010 paediatric guidelines
More informationCompounding al Oral Liquid Available
ORAL ANTIRETROVIRAL ADMINISTRATION: INFORMATION ON CRUSHING AND LIQUID DRUG FORMULATIONS Drug Oral Preparation Case Reports/Clinical Combination Products: Atripla (efavirenz/ emtricitabine/ tenofovir DF)
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationFriday afternoon Programme
Friday afternoon Programme Pharmacology and TDM Dr Marta Boffito Consultant Physician, C&W Resistance to new anti-retrovirals Dr Steve Taylor Consultant Physician, Birmingham HIVPA Annual Conference 2008
More informationDidactic Series. Switching Regimens in the Setting of Virologic Suppression
Didactic Series Switching Regimens in the Setting of Virologic Suppression Craig Ballard, PharmD, AAHIVP UC San Diego Health Owen Clinic June 14 th, 2018 1 Learning Objectives 1) Describe DHHS guidelines
More informationWhen to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc
When to Start ART Exact CD4 count at which to initiate therapy not known, but evidence points to starting at higher counts Current recommendation: ART for all patients with CD4 count of
More informationWhat is the most important information I should know about tenofovir? What should I discuss with my healthcare provider before taking tenofovir?
1 of 6 6/10/2016 4:33 PM Generic Name: tenofovir (ten OF oh vir) Brand Name: Viread What is tenofovir? Tenofovir is an antiviral medicine that prevents human immunodeficiency virus (HIV) or hepatitis B
More informationFLAMINGO 96-WEEK PRESENTATION DATA
FLAMINGO 96-WEEK PRESENTATION DATA Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects UK/DLG/0083/14j(4) Date of preparation: August 2017 Prescribing information is available at the
More informationConcomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications.
Avifanz Tablet Description Avifanz is the brand name for Efavirenz. Efavirenz, a synthetic antiretroviral agent, is a non-nucleoside reverse transcriptase inhibitor. While Efavirenz is pharmacologically
More informationHIV/AIDS Prenatal Care for HIV+ Mothers. 1. Algorithm for Prenatal Screening & Care (Antepartum)
1. Algorithm for Prenatal Screening & Care (Antepartum) 2. Algorithm for Prenatal HIV Screening and Care (Mother refuses screening) 3. Algorithm for Intrapartum Care 4. Prenatal Care for HIV+ Mothers a.
More informationTHE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010 The South African Antiretroviral Treatment Guidelines 2010 Goals of the programme Achieve best health outcomes in the most cost-efficient manner
More informationORAL ANTIRETROVIRAL ADMINISTRATION: INFORMATION ON CRUSHING AND LIQUID DRUG FORMULATIONS
ORAL ANTIRETROVIRAL ADMINISTRATION: INFORMATION ON CRUSHING AND LIQUID DRUG FORMULATIONS Drug Preparation Case Reports/Clinical Combination Products: Atripla (efavirenz/ emtricitabine/ tenofovir DF) no
More informationPharmacologic Characteristics and Delivery Options for Integrase Inhibitors
Pharmacologic Characteristics and Delivery Options for Integrase Inhibitors Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious
More informationConstructing antiretroviral regimens to overcome imperfect adherence
Constructing antiretroviral regimens to overcome imperfect adherence Amanda H. Corbett, PharmD, BCPS, FCCP, AAHIVE 7 th International Conference on HIV Treatment and Prevention Adherence June 4, 2012 Miami
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationCurrent HIV Treatment A different challenge every time. Sonali Sonecha Lead HIV Pharmacist 22 nd September 2016
Current HIV Treatment A different challenge every time Sonali Sonecha Lead HIV Pharmacist 22 nd September 2016 Aims At the end of this session, delegates should be able to Apply the principles of antiretroviral
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationCost impact of an HIV MDT for managing anti-retroviral switch
Cost impact of an HIV MDT for managing anti-retroviral switch 2016 ST4 Farnaz Dave Infectious Diseases & General Internal Medicine Mr Ian Sayers Specialist Infectious Diseases Pharmacist Dr Fahar Niazi
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationPATIENT INFORMATION VIREAD
PATIENT INFORMATION VIREAD (VEER-ee-ad) (tenofovir disoproxil fumarate) tablets and oral powder Read this Patient Information before you start taking VIREAD and each time you get a refill. There may be
More informationThe Medicines Patent Pool: An Update. June 2012 Geneva, Switzerland
The Medicines Patent Pool: An Update June 2012 Geneva, Switzerland The Medicines Patent Pool Royalties Licensor Licensor Patents Generics versions of existing compounds Licensor Licensor Patents Patents
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationSA HIV Clinicians Society Adult ART guidelines
SA HIV Clinicians Society Adult ART guidelines In draft format Graeme Meintjes (on behalf of the guidelines committee) Selected topics When to start ART First-line Second-line Third-line Patients with
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationOverview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course
Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED Acknowledgments - Dr. Christina Polyak - Dr. Julie Ake Disclaimer The views expressed in this presentation are
More informationPractical Scenarios Calculating doses for newborns. Karen Buckberry
Practical Scenarios Calculating doses for newborns Karen Buckberry Real Life Midwife phones you HIV+ mother in labour Needs you to tell Dr what meds to prescribe for baby What info do you need? Info needed
More informationRisk of HIV-1 low level viremia to treatment. Germany. Nadine Lübke Düsseldorf
Risk of HIV-1 low level viremia to treatment failure in the AREVIR-RESINA cohort in Germany Nadine Lübke Düsseldorf FDA Approval of antiretroviral drugs 1980-84 1985-89 1990-94 1995-99 2000-04 2005-09
More informationAddressing Pediatric Needs of the Most Neglected: next steps
Addressing Pediatric Needs of the Most Neglected: next steps An updated overview of DNDi Pediatric Focus Nathalie Strub Wourgaft (Medical Director) Janice Lee (HIV Pediatric Clinical Manager) A Fatal Imbalance
More informationThe Hospitalized HIV+ Patient
The Hospitalized HIV+ Patient Danny Toub MD dannyt@srheathcenters.org October 8, 2012 Santa Rosa Family Medicine Residency List 3 ways of risk-stratifying known or suspected HIV+ inpatients Perform differential
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationnevirapine, zidovudine and lamivudine
nevirapine, zidovudine and lamivudine a fixed dose ART combination for HIV treatment http://www.aidsmap.com/hatip nevirapine. zidovudine and lamivudine (non-fixed dose) 2 Information on starting treatment
More informationIATT Optimal List of Paediatric ARV Formulations: Background and Update
IATT Optimal List of Paediatric ARV Formulations: Background and Update Nandita Sugandhi Clinton Health Access Initiative, USA PADO/IATT Update for ARV Manufacturers October 19, 2015 Overview Rationale
More informationnevirapine, stavudine and lamivudine
nevirapine, stavudine and lamivudine Information on starting treatment with: nevirapine (NVP) + stavudine (d4t) + lamivudine (3TC) Nevirapine, stavudine and lamivudine (non-fixed dose) 2 Lead in dosing
More informationHIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationOctober 26-28: Training Day 1
Peer Linkage and Re-Engagement of HIV- Positive Women of Color October 26-28: Training Day 1 Peer Linkage and Re -Engagement of HIV - Positive Women of Color Convening Training Trainers Today: Alicia Downes
More informationAppropriate Use & Safety Edits
Appropriate Use & Safety Edits Envolve Pharmacy Solutions provides a variety of safety edits to promote the use of the right medication, in the right patient, at the right time. These edits are routinely
More informationGuidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters
Guidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationHIV epidemiology since HIV in the United States. HIV Transmission
HIV epidemiology since 1999 8% increase in HIV diagnoses Men who have sex with men (MSM) increased 14% Heterosexual increased 10% IVDU decrease about 30% Young Black MSM 15% incidence HIV in the United
More informationIndustry Data Request
Industry Data Request Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts,
More informationThe Annotated Bibliography of the UCSF HIV Solid Organ Transplantation Project. ARV Dosing in End Stage Renal Disease
The Annotated Bibliography of the UCSF HIV Solid Organ Transplantation Project ARV Dosing in End Stage Renal Disease 1. Jayasekara, D., Aweeka, F. T., Rodriguez, R., Kalayjian, R. C., Humphreys, M. H.,
More informationSELECTING THE BEST ART FOR EACH PATIENT
SELECTING THE BEST ART FOR EACH PATIENT Corklin R Steinhart, MD, PhD Head, Global Medical Directors ViiV Healthcare CNVX/HIVP/0025/16 5th Asian Conference on Hepatitis & AIDS 第五届亚洲肝炎与艾滋病学术会议 28-29 May
More informationStarting Immediate Treatment for HIV-1
Starting Immediate Treatment for HIV-1 Ronald P. Hattis, MD, MPH Email: ronhattis@foundation.beyondaids.org Associate Prof. of Preventive Medicine, Loma Linda University Secretary, Beyond AIDS Foundation
More informationAn HIV Update Jan Clark, PharmD Specialty Practice Pharmacist
An HIV Update - 2019 Jan Clark, PharmD Specialty Practice Pharmacist 2 The goal of this program is to provide a review and update of HIV care and to provide a forum for discussing the current local and
More information